Why Abeona Therapeutics Inc.’s (ABEO) Stock Is Down 5.36%
As of Monday, July 20, Abeona Therapeutics Inc.’s ABEO share price has dipped by 5.36%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Commentary & Analysis
Why Abeona Therapeutics Inc.’s (ABEO) Stock Is Down 5.24%
As of Thursday, May 07, Abeona Therapeutics Inc.’s ABEO share price has dipped by 5.24%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Abeona Therapeutics Inc.’s (ABEO) Stock Is Up 7.29%
As of Monday, May 04, Abeona Therapeutics Inc.’s ABEO share price has surged by 7.29%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Abeona Therapeutics Inc.’s (ABEO) Stock Is Down 5.47%
As of Friday, April 10, Abeona Therapeutics Inc.’s ABEO share price has dipped by 5.47%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Abeona Therapeutics Inc.’s (ABEO) Stock Is Up 5.35%
As of Thursday, April 02, Abeona Therapeutics Inc.’s ABEO share price has surged by 5.35%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ABEO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $368.8 | $251.9 | 34% |
|
| Shares Out (Mil) | 56.6 | 50.8 | 51% |
|
| Institutional Ownership | 75.1% | 92.0% | 45% |
|
| Float (Mil) | 36.6 | 40.5 | 41% |
|
| Beta | 1.34 | 0.95 | 77% |
|
| Avg Daily Volume (000s) | 1,112 | 447 | 73% |
|
| Price Change (52-week) |
(4.2%) | 54.2% | 42% |
|
| Growth | ABEO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (10.3%) | 14.0% | 5% |
|
| Net Income (5yr) | 23.3% | (9.8%) | 77% |
|
| EPS (5yr) | 15.4% | 16.3% | 57 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.2% | (15.6%) | 73% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.233) | ($0.683) | $0.287 | |
| Month Ago EPS | ($0.233) | ($0.683) | $0.287 | |
| # Rev Up | 2 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.290) | ($0.907) | $0.240 | |
| Year/Year Chg | (22.8%) | (167.4%) | (4.3%) | |
| Financials | ABEO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $15 | $39 | 11% |
|
| Net Income (TTM) (Mil) | $66 | ($43) | 57% |
|
| EPS (TTM) | $1.210 | ($1.600) | 64% |
|
| Operating Cash Flow (TTM) (Mil) | ($78) | ($30) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $45 | $3 | 70% |
|
| Long-Term Debt (Q1) (Mil) | $9 | $5 | 28% |
|
| Enterprise Value (Q1) (Mil) | $180 | $182 | 25% |
|
| Valuation | ABEO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.54 | 2.60 | 59% |
|
| P/E | 7.1 | 18.6 | 8% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.5 | 0.9 | 21% |
|
| Ratios | ABEO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (123.8%) | 63.8% | 2% |
|
| Net Margin | 454.9% | (64.7%) | 100% |
|
| ROA | 44.4% | (49.7%) | 99% |
|
| ROE | 71.0% | (55.4%) | 95% |
|
| Liabilities to Assets | 27.0% | 30.3% | 18% |
|
| F-Score | 4 | 3 | 34% |
|
Passing Stock Screens
As of 7/30/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Magic Formula Screen
Factors: Value, Quality
Joel Greenblatt's investing approach is based on finding companies with high return on investment that are trading for less than they are worth.
| Performance Since Inception: | 6.9% |
| +/- S&P 500: | -0.6 |
